Chimeric protein consisting of 3M2e and HSP as a universal influenza vaccine candidate: from in silico analysis to preliminary evaluation.
Amino Acid Sequence
Animals
Antibodies, Viral
/ immunology
Databases, Genetic
Epitopes
/ chemistry
Female
Gene Expression
Heat-Shock Proteins
/ chemistry
Humans
Immunogenicity, Vaccine
Influenza Vaccines
/ immunology
Influenza, Human
/ immunology
Mice
Recombinant Fusion Proteins
/ chemistry
Reproducibility of Results
Structure-Activity Relationship
Viral Matrix Proteins
/ chemistry
Fusion protein
HSP70
Influenza virus
M2e
Universal vaccine
in silico
Journal
Virus genes
ISSN: 1572-994X
Titre abrégé: Virus Genes
Pays: United States
ID NLM: 8803967
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
02
06
2018
accepted:
22
10
2018
pubmed:
2
11
2018
medline:
23
2
2019
entrez:
2
11
2018
Statut:
ppublish
Résumé
The 23-amino acid ectodomain of influenza virus M2 protein (M2e) is highly conserved among human influenza virus variants and represents an attractive target for developing a universal vaccine. Although this peptide has limited potency and low immunogenicity, the degree of M2e density has been shown to be a critical factor influencing the magnitude of epitope-specific responses. The aim of this study was to design a chimer protein consisting of three tandem repeats of M2e peptide sequence fused to the Leishmania major HSP70 gene and evaluate its characteristics and immunogenicity. The structure of the deduced protein and its stability, aliphatic index, biocomputed half-life and the anticipated immunogenicity were analyzed by bioinformatics software. The oligonucleotides encoding 3M2e and chimer 3M2e-HSP70 were expressed in Escherichia coli and affinity purified. The immunogenicity of the purified recombinant proteins was preliminary examined in mouse model. It was predicted that fusion of HSP70 to the C-terminal of 3M2e peptide led to increased stability, hydropathicity, continuous B cell epitopes and antigenic propensity score of chimer protein. Also, the predominant 3M2e epitopes were not hidden in the chimer protein. The initial in vivo experiment showed that 3M2e-HSP chimer protein stimulates specific immune responses. In conclusion, the results of the current study suggest that 3M2e-HSP chimer protein would be an effective universal subunit vaccine candidate against influenza infection.
Identifiants
pubmed: 30382564
doi: 10.1007/s11262-018-1609-5
pii: 10.1007/s11262-018-1609-5
doi:
Substances chimiques
Antibodies, Viral
0
Epitopes
0
Heat-Shock Proteins
0
Influenza Vaccines
0
M2 protein, Influenza A virus
0
Recombinant Fusion Proteins
0
Viral Matrix Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22-32Subventions
Organisme : pasteur institute of Iran
ID : 759
Références
Khanna M, Sharma S, Kumar B, Rajput R (2014) Protective immunity based on the conserved hemagglutinin stalk domain and its prospects for universal influenza vaccine development. BioMed Res Int. https://doi.org/10.1155/2014/546274
doi: 10.1155/2014/546274
pubmed: 25184147
pmcid: 4145737
Munster VJ, Baas C, Lexmond P, Waldenstrom J, Wallensten A, Fransson T, Rimmelzwaan GF, Beyer W, Schutten M, Olsen B (2007) Spatial, temporal, and species variation in prevalence of influenza A viruses in wild migratory birds. PLoS Pathog 3(5):e61
doi: 10.1371/journal.ppat.0030061
pmcid: 1876497
pubmed: 17500589
Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM (2004) Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 4:499–509
doi: 10.1016/S1473-3099(04)01105-3
pubmed: 15288823
https://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm
Frace AM, Klimov AI, Rowe T, Black RA, Katz JM (1999) Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 17:2237–2244
doi: 10.1016/S0264-410X(99)00005-5
pubmed: 10403591
De Filette M, Ramne A, Birkett A, Lycke N, Löwenadler B, Min Jou W, Saelens X, Fiers W (2006) The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24:544–551
doi: 10.1016/j.vaccine.2005.08.061
pubmed: 16169634
Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, Baz M, Abed Y, Savard C, Pare C, Lopez Macias C, Boivin G, Leclerc D (2008) Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 26:3340–3395
doi: 10.1016/j.vaccine.2008.04.052
Wu F, Huang JH, Yuan XY, Huang WS, Chen YH (2007) Characterization of immunity induced by M2e of influenza virus. Vaccine 25:8868–8873
doi: 10.1016/j.vaccine.2007.09.056
pubmed: 18061317
Zhang X, Liu M, Liu C, Du J, Shi W, Sun E, Li H, Li J, Zhang Y (2011) Vaccination with different M2e epitope densities confers partial protection against H5N1 influenza A virus challenge in chickens. Intervirology 54:290–299
doi: 10.1159/000319440
pubmed: 21228535
Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans RK, Umlauf S, Tussey L, Powell TJ (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26:201–214
doi: 10.1016/j.vaccine.2007.10.062
pubmed: 18063235
Farzanehpour M, Soleimanjahi H, Hassan ZM, Amanzadeh A, Ghaemi A, Fazeli M (2013) HSP70 modified response against HPV based tumor. Eur Rev Med Pharmacol Sci 17:228–234
pubmed: 23377813
Li J, Li KN, Gao J, Cui JH, Liu YF, Yang SJ (2008) Heat shock protein 70 fused to or complexed with hantavirus nucleocapsid protein significantly enhances specific humoral and cellular immune responses in C57BL/6 mice. Vaccine 26:3175–3187
doi: 10.1016/j.vaccine.2008.02.066
pubmed: 18479786
Kaur J, Kaur T, Kaur S (2011) Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice. Acta Trop 119:50–56
doi: 10.1016/j.actatropica.2011.04.007
pubmed: 21530477
Doytchinova IA1, Flower DR (2007) VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinform 8:4
doi: 10.1186/1471-2105-8-4
CombetC BlanchetC, Geourjon C, Deléage G (2000) NPS@: network protein sequence analysis. Trends Biochem Sci 25(3):147–150
doi: 10.1016/S0968-0004(99)01540-6
Schowed T, Kopp J, Guex N, Peitch MC (2003) SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acid Res 31(13):3381–3385
doi: 10.1093/nar/gkg520
Yang J, Zhang Y (2015) I-TASSER server: new development for protein structure and function predictions. Nucleic Acids Res 43(W1):W174–W181
doi: 10.1093/nar/gkv342
pmcid: 4489253
pubmed: 25883148
Lovell SC, Davis IW, Arendall WB 3rd, de Bakker PI, Word JM, Prisant MG, Richardson JS, Richardson DC (2003) Structure validation by calpha geometry: phi, psi and cbeta deviation. Proteins 50:437–450
doi: 10.1002/prot.10286
pubmed: 12557186
Ansari HR, Raghava GP (2010) Identification of conformational B-cell Epitopes in an antigen from its primary sequence. Immunome Res 6:6
doi: 10.1186/1745-7580-6-6
pmcid: 2974664
pubmed: 20961417
Ponomarenko J, Bui HH, Li W, Fusseder N, Bourne PE, Sette A et al (2008) ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinform 9(1):514. https://doi.org/10.1186/1471-2105-9-514
doi: 10.1186/1471-2105-9-514
Singh H, Raghava GP (2001) ProPred: prediction of HLA-DR binding sites. Bioinformatics 17:1236–1237
doi: 10.1093/bioinformatics/17.12.1236
pubmed: 11751237
Singh H, Raghava GP (2003) ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics 19:1009–1014
doi: 10.1093/bioinformatics/btg108
pubmed: 12761064
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227(5259):680–685
doi: 10.1038/227680a0
Fotouhi F, Shaffifar M, Farahmand B, Shirian S, Saeidi M, Tabarraei A, Gorji A, Ghaemi A (2017) Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus. Arch Virol 162:1251–1260
doi: 10.1007/s00705-017-3230-7
pubmed: 28120096
Shaw A (2011) Conserved proteins as potential universal vaccines. In: Rappuoli R, Del Giudice G (eds) Influenza vaccines for the future. Springer, Basel, pp 313–325
doi: 10.1007/978-3-0346-0279-2_13
Wang Y, Zhou L, Shi H, Xu H, Yao H, Xi XG, Toyoda T, Wang X, Wang T (2009) Monoclonal antibody recognizing SLLTEVET epitope of M2 protein potently inhibited the replication of influenza A viruses in MDCK cells. Biochem Biophys Res Commun 385:118–122
doi: 10.1016/j.bbrc.2009.04.129
pubmed: 19410554
Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR (1990) Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 64:1375–1377
pmcid: 249260
pubmed: 2304147
Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, Garsky VM, Ionescu R, Rippeon Y, Shi L, Chastain MA, Condra JH, Davies ME, Liao J, Emini EA, Shiver JW (2004) Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22:2993–3003
doi: 10.1016/j.vaccine.2004.02.021
pubmed: 15297047
Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5(10):1157–1163
doi: 10.1038/13484
pubmed: 10502819
pmcid: 10502819
Eliasson DG, El Bakkouri K, Schön K, Ramne A, Festjens E, Löwenadler B, Fiers W, Saelens X, Lycke N (2008) A novel mucosal adjuvant targeted influenza vaccine. Vaccine 26:1243–1252
doi: 10.1016/j.vaccine.2007.12.027
pubmed: 18243429
Feng J, Zhang M, Mozdzanowska K, Zharikova D, Hoff H, Wunner W, Couch RB, Gerhard W (2006) Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 3:102
doi: 10.1186/1743-422X-3-102
pmcid: 1702354
pubmed: 17150104
Liu W, Chen YH (2005) High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: a novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins. Eur J Immunol 35:505–514
doi: 10.1002/eji.200425749
pubmed: 15627976
Babapoor S, Neef T, Mittelholzer C, Girshick T, Garmendia A, Shang H, Khan MI, Burkhard P (2011) A novel vaccine using nanoparticle platform to present immunogenic M2e against avian influenza infection. Influenza Res Treat 2011:126794
pubmed: 23074652
Kilic A, Mandal K (2012) Heat shock proteins: pathogenic role in atherosclerosis and potential therapeutic implications. Autoimmune Dis 2012:502813
pmcid: 3530228
pubmed: 23304456
Ebrahimi SM, Dabaghian M, Tebianian M, Jazi MH (2012) In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran. Virology 430:63–72
doi: 10.1016/j.virol.2012.04.015
pubmed: 22595444
Rafati S, Gholami E, Hassani N, Ghaemimanesh F, Taslimi Y, Taheri T, Soong L (2007) Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. Vaccine 25:4159–4169
doi: 10.1016/j.vaccine.2007.03.006
pubmed: 17395340
Crasto CJ, Feng JA (2000) LINKER: a program to generate linker sequences for fusion proteins. Protein Eng 13:309–312
doi: 10.1093/protein/13.5.309
pubmed: 10835103
George RA, Heringa J (2002) An analysis of protein domain linkers: their classification and role in protein folding. Protein Eng 15:871–879
doi: 10.1093/protein/15.11.871
pubmed: 12538906
Argos P (1990) An investigation of oligopeptides linking domains in protein tertiary structures and possible candidates for general gene fusion. J Mol Biol 211:943–958
doi: 10.1016/0022-2836(90)90085-Z
pubmed: 2313701
Fu TM, Grimm KM, Citron MP, Freed DC, Fan J, Keller PM, Shiver JW, Liang X, Joyce JG (2009) Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 27:1440–1447
doi: 10.1016/j.vaccine.2008.12.034
pubmed: 19146898
Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, Brown SA, Makarova N, Perez DR, Macdonald GH, McCullers JA (2006) Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13(9):981–990
doi: 10.1128/CVI.00156-06
pmcid: 1563571
pubmed: 16960108
Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310:1510–1512
doi: 10.1126/science.1118948
pubmed: 16322460
Shokouhi H, Farahmand B, Ghaemiph A, Mazaheri V, Fotouhi F (2018) Vaccination with three tandem repeats of M2 extracellular domain fused to Leismania major HSP70 protects mice against influenza A virus challenge. Virus Res 251:40–46
doi: 10.1016/j.virusres.2018.05.003
pubmed: 29730305